select semaglutide trial Trial: Cuts Major CVD Risk by 20% in Overweight/Obese Adults Without Diabetes Full SELECT Results Affirm CV

FiberSMART has also been shown to promote the growth of beneficial bacteria like Bifidobacteria and Akkermansia muciniphila

Ralto KM, Parikh SM

(PubMed) Pazdro R, Burgess JR

Given the small sample size, absence of a comparator group, heterogeneous follow-up, and limitations inherent to retrospective data collection, no conclusions regarding glycemic efficacy, cardiovascular safety, or overall safety profile can be drawn

Dosing ranges from 0.25 mg to 2.4 mg weekly for semaglutide, 0.75 mg to 4.5 mg weekly for dulaglutide, and 0.6 mg to 3 mg daily for liraglutide, with your healthcare provider determining the optimal dose based on glycemic control, tolerability, renal function, and cardiovascular risk factors